Boston Scientific Co. (NYSE:BSX) Shares Purchased by Mount Yale Investment Advisors LLC

Mount Yale Investment Advisors LLC boosted its holdings in Boston Scientific Co. (NYSE:BSX) by 8.8% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 16,869 shares of the medical equipment provider’s stock after purchasing an additional 1,370 shares during the quarter. Mount Yale Investment Advisors LLC’s holdings in Boston Scientific were worth $1,155,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in BSX. Norges Bank acquired a new position in Boston Scientific in the fourth quarter valued at $930,626,000. Putnam Investments LLC increased its stake in Boston Scientific by 110.5% during the fourth quarter. Putnam Investments LLC now owns 13,067,570 shares of the medical equipment provider’s stock worth $755,436,000 after acquiring an additional 6,859,280 shares during the last quarter. Capital World Investors increased its stake in Boston Scientific by 236.1% during the fourth quarter. Capital World Investors now owns 9,419,829 shares of the medical equipment provider’s stock worth $544,560,000 after acquiring an additional 6,617,360 shares during the last quarter. Capital Research Global Investors acquired a new stake in Boston Scientific during the first quarter worth about $182,897,000. Finally, Vanguard Group Inc. increased its stake in Boston Scientific by 1.6% during the first quarter. Vanguard Group Inc. now owns 127,437,884 shares of the medical equipment provider’s stock worth $8,728,221,000 after acquiring an additional 1,988,082 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on BSX shares. Raymond James upped their target price on Boston Scientific from $85.00 to $91.00 and gave the stock a “strong-buy” rating in a research report on Thursday. BTIG Research upped their target price on Boston Scientific from $80.00 to $84.00 and gave the stock a “buy” rating in a research report on Monday, July 15th. JPMorgan Chase & Co. upped their price objective on Boston Scientific from $82.00 to $85.00 and gave the company an “overweight” rating in a research note on Thursday. Needham & Company LLC upped their price objective on Boston Scientific from $82.00 to $86.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Morgan Stanley upped their price objective on Boston Scientific from $79.00 to $92.00 and gave the company an “overweight” rating in a research note on Monday, July 15th. Two equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $84.76.

Boston Scientific Stock Performance

BSX traded up $0.67 during trading hours on Monday, hitting $75.59. The company’s stock had a trading volume of 6,940,578 shares, compared to its average volume of 6,302,185. The company has a 50-day simple moving average of $76.49 and a 200 day simple moving average of $70.47. The company has a current ratio of 1.66, a quick ratio of 1.14 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $110.90 billion, a PE ratio of 63.13, a PEG ratio of 2.55 and a beta of 0.78. Boston Scientific Co. has a fifty-two week low of $48.35 and a fifty-two week high of $79.43.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.04. The firm had revenue of $4.12 billion during the quarter, compared to analyst estimates of $4.02 billion. Boston Scientific had a return on equity of 16.80% and a net margin of 12.00%. The firm’s quarterly revenue was up 14.5% on a year-over-year basis. During the same period last year, the company posted $0.53 EPS. As a group, sell-side analysts expect that Boston Scientific Co. will post 2.4 EPS for the current year.

Insider Transactions at Boston Scientific

In other news, EVP John Bradley Sorenson sold 17,587 shares of the firm’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $71.50, for a total transaction of $1,257,470.50. Following the completion of the sale, the executive vice president now directly owns 50,638 shares of the company’s stock, valued at approximately $3,620,617. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, EVP John Bradley Sorenson sold 17,587 shares of the firm’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $71.50, for a total transaction of $1,257,470.50. Following the completion of the sale, the executive vice president now directly owns 50,638 shares of the company’s stock, valued at approximately $3,620,617. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Charles J. Dockendorff sold 3,946 shares of the firm’s stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $72.70, for a total value of $286,874.20. The disclosure for this sale can be found here. Insiders sold a total of 62,441 shares of company stock valued at $4,624,453 in the last three months. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.